The institutional landscape for Enliven Therapeutics, Inc. (NASDAQ:ELVN) includes 124 filers as of the latest reporting cycle ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 31 Dec, 2025 | 7,959,538 | 0 | 0.00% | $122,576,885.00 |
| FMR LLC | 31 Dec, 2025 | 7,107,635 | -21,561 | -0.30% | $109,457,572.00 |
| Commodore Capital LP | 31 Dec, 2025 | 4,692,809 | 0 | 0.00% | $72,269,259.00 |
| Vestal Point Capital, LP | 31 Dec, 2025 | 3,830,000 | 2,670,000 | 230.17% | $58,982,000.00 |
| Fairmount Funds Management LLC | 31 Dec, 2025 | 3,711,444 | 0 | 0.00% | $57,156,238.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,613,326 | 94,802 | 2.69% | $55,645,219.00 |
| Polar Capital Holdings Plc | 31 Dec, 2025 | 3,513,680 | 418,673 | 13.53% | $54,110,672.00 |
| VR Adviser, LLC | 31 Dec, 2025 | 3,226,331 | 0 | 0.00% | $49,685,497.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 2,801,665 | 248,651 | 9.74% | $43,145,640.00 |
| JANUS HENDERSON GROUP PLC | 31 Dec, 2025 | 1,671,724 | -121,859 | -6.79% | $25,744,550.00 |
| Point72 Asset Management, L.P. | 31 Dec, 2025 | 1,504,601 | 464,191 | 44.62% | $23,170,855.00 |
| Novo Holdings A/S | 31 Dec, 2025 | 1,480,000 | 53,740 | 3.77% | $22,792,000.00 |
| CITADEL ADVISORS LLC | 31 Dec, 2025 | 1,424,344 | 263,841 | 22.74% | $21,934,897.00 |
| Capital Research Global Investors | 31 Dec, 2025 | 1,304,346 | -11,119 | -0.85% | $20,086,928.00 |
| Pictet Asset Management Holding SA | 31 Dec, 2025 | 1,303,235 | -94,852 | -6.78% | $20,069,819.00 |
| STATE STREET CORP | 31 Dec, 2025 | 1,052,862 | 87,725 | 9.09% | $16,214,075.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 1,048,722 | -36,291 | -3.34% | $16,153,779.00 |
| Soleus Capital Management, L.P. | 31 Dec, 2025 | 1,025,000 | 1,025,000 | 0.00% | $15,785,000.00 |
| Blackstone Inc. | 31 Dec, 2025 | 954,946 | -365,646 | -27.69% | $14,706,168.00 |
| Rock Springs Capital Management LP | 31 Dec, 2025 | 798,405 | 112,298 | 16.37% | $12,295,437.00 |